MBOT vs. AIM, APYX, SEPA, CTCX, NUVO, DRIO, LNSR, ICCM, CTSO, and LUCD
Should you be buying Microbot Medical stock or one of its competitors? The main competitors of Microbot Medical include AIM ImmunoTech (AIM), Apyx Medical (APYX), SEP Acquisition (SEPA), Carmell (CTCX), Holdco Nuvo Group D.G (NUVO), DarioHealth (DRIO), LENSAR (LNSR), IceCure Medical (ICCM), Cytosorbents (CTSO), and Lucid Diagnostics (LUCD).
Microbot Medical (NASDAQ:MBOT) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.
16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 10.6% of Microbot Medical shares are owned by insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Microbot Medical has higher earnings, but lower revenue than AIM ImmunoTech. Microbot Medical is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
Microbot Medical received 290 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 82.35% of users gave AIM ImmunoTech an outperform vote while only 70.61% of users gave Microbot Medical an outperform vote.
Microbot Medical presently has a consensus target price of $7.00, indicating a potential upside of 566.79%. Given Microbot Medical's higher probable upside, analysts clearly believe Microbot Medical is more favorable than AIM ImmunoTech.
In the previous week, AIM ImmunoTech had 1 more articles in the media than Microbot Medical. MarketBeat recorded 3 mentions for AIM ImmunoTech and 2 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 1.89 beat AIM ImmunoTech's score of -1.80 indicating that Microbot Medical is being referred to more favorably in the media.
Microbot Medical has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -16,123.32%. Microbot Medical's return on equity of -149.24% beat AIM ImmunoTech's return on equity.
Microbot Medical has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.
Summary
Microbot Medical beats AIM ImmunoTech on 11 of the 16 factors compared between the two stocks.
Get Microbot Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Microbot Medical Competitors List
Related Companies and Tools
